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Abstract
Background: Multimorbidity is associated with negative effects both on people’s health and on healthcare systems.
A key problem linked to multimorbidity is polypharmacy, which in turn is associated with increased risk of partly
preventable adverse effects, including mortality. The Ariadne principles describe a model of care based on a
thorough assessment of diseases, treatments (and potential interactions), clinical status, context and preferences
of patients with multimorbidity, with the aim of prioritizing and sharing realistic treatment goals that guide an
individualized management. The aim of this study is to evaluate the effectiveness of a complex intervention that
implements the Ariadne principles in a population of young-old patients with multimorbidity and polypharmacy.
The intervention seeks to improve the appropriateness of prescribing in primary care (PC), as measured by the
medication appropriateness index (MAI) score at 6 and 12 months, as compared with usual care.
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Methods/Design: Design: pragmatic cluster randomized clinical trial. Unit of randomization: family physician (FP).
Unit of analysis: patient. Scope: PC health centres in three autonomous communities: Aragon, Madrid, and
Andalusia (Spain). Population: patients aged 65–74 years with multimorbidity (≥3 chronic diseases) and
polypharmacy (≥5 drugs prescribed in ≥3 months). Sample size: n = 400 (200 per study arm). Intervention: complex
intervention based on the implementation of the Ariadne principles with two components: (1) FP training and (2)
FP-patient interview. Outcomes: MAI score, health services use, quality of life (Euroqol 5D-5L), pharmacotherapy and
adherence to treatment (Morisky-Green, Haynes-Sackett), and clinical and socio-demographic variables. Statistical
analysis: primary outcome is the difference in MAI score between T0 and T1 and corresponding 95% confidence
interval. Adjustment for confounding factors will be performed by multilevel analysis. All analyses will be carried out
in accordance with the intention-to-treat principle.
Discussion: It is essential to provide evidence concerning interventions on PC patients with polypharmacy and
multimorbidity, conducted in the context of routine clinical practice, and involving young-old patients with
significant potential for preventing negative health outcomes.
Trial registration: Clinicaltrials.gov, NCT02866799
Background
Multimorbidity, the presence of various chronic diseases
in the same individual, is the norm among the elderly
population and very prevalent in the adult population in
most Western European countries [1–3]. In Spain, the
latest National Health Survey reports that individuals of
over 75 years of age have an average of 3.2 chronic
health problems, while the so-called young-old popula-
tion (65–74 years) has an average of 2.8. Most studies
define multimorbidity as the concurrent presence of two
or more or three or more chronic diseases; the latter
definition is more suitable for the identification of
patients with complex health needs [4].
The potential negative health impacts of multimorbidity
include reduced quality of life and functional capacity,
inadequate use of health services, and increased complica-
tions and healthcare costs [5–7]. These effects are partly
attributable to the current model of healthcare, which is
essentially organized and designed to address diseases
individually [8–10].
Although there is emerging evidence to support policy
for the management of people with multimorbidity, the
effectiveness of interventions is still uncertain [11], as is
the case for clinical practice guidelines (CPGs) for
patients with comorbidity [12]. The reality is that uncrit-
ical application of the recommendations of multiple CPGs
for concurrent diseases in the same patient increases the
likelihood of polypharmacy, defined by consensus as the
simultaneous consumption of five or more drugs [13].
Family physicians (FP) have reported that this is a daily
reality in primary care (PC) [14].
Polypharmacy implies an increased risk of medication-
related problems such as interactions and adverse drug
reactions, underuse of necessary treatments, low adher-
ence, and partly preventable mortality, in particular in
older patients [15]. Inappropriate choice of drugs with
regard to age is another major problem, for which alter-
native (safer) approaches have been proposed that are
equally or more effective [16].
Multiple approaches have been designed to measure
and reduce inappropriate prescribing [17]. Explicit mea-
sures assess prescriptions according to predefined
criteria related to the properties of the drugs concerned
(e.g. Beers [18] and STOPP/START criteria [19]). How-
ever, these criteria may fall short in patients with
multiple diseases and (interacting) treatments [20].
Therefore, implicit measures are applied to determine
the level of appropriateness of prescribing. Based on the
clinical judgment of the rater, implicit measures take
into account the health status of the individual patient.
The implicit method that is most accepted and validated,
both internationally and in Spain, is the medication
appropriateness index (MAI) [21, 22].
Evidence supporting the effectiveness of interventions
to improve outcomes in patients with multimorbidity
remains scarce [8, 23]. The Cochrane systematic review
by Smith et al. [24] concluded that drug prescribing and
adherence tend to improve when interventions target
risk factors of multimorbidity and when they focus on
key issues or specific functional difficulties affecting
patients. Another Cochrane systematic review [25]
evaluating the effectiveness of interventions aimed at
minimizing the negative effects of polypharmacy con-
cluded that, despite an overall improvement in prescrib-
ing by physicians, the effect on other clinical variables
such as hospital admissions and quality of life is unclear.
For this reason, the authors emphasized the need to
incorporate into clinical trial outcome variables of rele-
vance both for clinicians and patients and to evaluate
intervention costs.
Various care programmes have been implemented in
Spain to address polypharmacy in elderly patients
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(>75 years) by means of a systematic medication review
in PC, and this strategy is supported by some evidence
[26]. However, patients over 75 years of age constitute
only part of the population with multimorbidity. Fur-
thermore, these strategies do not meet the requirements
of patient-centred care where patient’s preferences are
taken into consideration. Shared decision making
between health professionals and patients is also thought
to improve patient’s adherence [27].
The sharing of common and realistic treatment goals
between physician and patient is essential to tackle
multimorbidity in the PC context and is the cornerstone
of the Ariadne principles [28]. The implementation of
these principles is based on a thorough assessment of
the diseases, treatments and potential treatment interac-
tions, global clinical status, and context of the patient by
the physician. This allows prioritization of patients’
health problems, taking into account their preferences
and wishes and ensuring their individualized manage-
ment and monitoring. Despite numerous studies demon-
strating the effectiveness of shared decision making on
health outcomes [29–31], the feasibility of implementa-
tion and the impact of the Ariadne principles in PC have
not been assessed to date, although the potential benefit
of implementing such a strategy in routine clinical
practice has been recognized [32, 33].
Objectives
Primary
The main objective is to evaluate the effectiveness of a
complex PC intervention implementing the Ariadne
principles on the improvement of medication appropri-
ateness in the young-old population with polypharmacy
and multimorbidity, as measured by the differences of
the MAI score at 6 months (T1) to baseline, compared
with usual care.
Secondary
(a)To evaluate the effects of the complex intervention
on medication appropriateness after 12 months (T2),
as well as on the use of health services, patient
quality of life, treatment adherence, and medication
safety, as compared with usual care.
(b)To study the cost-utility ratio of the intervention
as compared with that of usual care.
Method/design
Design
Pragmatic cluster randomized controlled clinical trial
with 12 months of follow-up. The unit of randomization
is the FP and the unit of analysis is the patient. A cost-
utility study will be performed from the perspective of
the funder with a time horizon of 1 year.
Scope of study
The scope of the study is the primary care setting of the
Spanish national health system.
Study population
The study population includes patients aged 65 to
74 years with multimorbidity and polypharmacy, attend-
ing PC health centres in three autonomous communities
(ACs) in Spain: Aragon, Madrid, and Andalusia.
FP selection criteria
– Employed in current position for at least 1 year.
– Stable employment situation, with no intention of
leaving their position during the course of the study.
– Agree to participate and provide written informed
consent.
Patient selection criteria
1. Inclusion criteria:
– Age 65 to 74 years.
– Multimorbidity, defined as ≥3 chronic diseases as
per O’Halloran [34].
– Polypharmacy, defined as ≥5 drugs prescribed
over at least the 3 months prior to inclusion in
the study.
– At least one visit to the FP in the past year.
– Agree to participate and provide written
informed consent.
2. Exclusion criteria:
– Institutionalized patients.
– Life expectancy of less than 12 months, as
determined by the FP.
– Mental and/or physical conditions considered by
the FP to prevent fulfilment of study requirements.
Sample size
The sample size was calculated under the hypothesis
that the intervention would lead to a difference of at
least 2 units in the change in MAI score at 6 months
(T1 vs T0) (i.e. a clinically relevant difference) between
study groups. Differences in MAI are assumed to be
normally distributed in each intervention arm and the
variances are assumed to be equal. According to previ-
ous studies, the standard deviation of the difference in
MAI is 6 units [32–34]. Therefore, the study should be
capable of detecting an effect size of 0.3 (2/6). Consider-
ing a power of 80% and assuming simple random
sampling, the required sample size would be 286
patients (143 patients in the intervention group and 143
in the control group).
The effective sample size in this type of study design
depends on the average size of the cluster and the
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degree of correlation between individuals in the cluster.
Accordingly, it is necessary to adjust the calculated
sample size in accordance with the design effect (DE).
An average cluster size of 5 patients per FP and an intra-
class correlation coefficient of 0.03 [35] produces the
following (DE = 1 + (5 − 1) × 0.03 = 1.12) which gives a
sample size, corrected for the DE, of 320 patients.
Assuming a percentage of losses of 20%, the final
sample size required is 400 patients (200 per group).
Assuming that each FP will recruit 5 patients, 80 FPs
(40 per group) will be required. In each AC, 133
patients will be recruited.
Recruitment
Voluntary participation will be proposed to FPs working
in PC health centres in each of the three ACs. Patients
will be added to a randomly ordered list of potential
participants provided that they fulfil the inclusion
criteria. Strategies to improve protocol adherence of
FP will be considered (e.g. individual follow-up of
protocol’s achievements and recognition via e-mail,
offer to participate as co-authors in scientific papers,
certified training sessions).
Each FP will consecutively select 5 patients from this
list. When a patient agrees to participate, the FP will
provide them with detailed information about the study,
confirm the inclusion/exclusion criteria, and obtain the
patient’s written informed consent. If they do not agree
to participate, data on the patient’s age, sex, and reason
for nonparticipation will be collected (see Fig. 1).
Randomization
The unit of randomization is the FP and the unit of ana-
lysis the patient. Randomization of the FP will be
achieved using the treatment assignment module of the
Epidat 4.1 program; the proposed intervention will be
considered the treatment and usual care considered the
control. To ensure an equal number of FPs in each
group (intervention and control), the ‘balanced groups’
option will be selected.
Once all participating FPs have selected their patients
and collected the corresponding baseline data, FP
randomization will be performed centrally by the Unidad
de Apoyo a la Investigación, Gerencia Asistencial de
Atención Primaria in Madrid. Subsequently, each FP will
receive the information on the study group to which
they have been assigned, at which point all patients
recruited by him or her will be included in that group.
Intervention
Intervention group
A complex intervention with two phases is conducted:
– First phase: FP training. This will consist of a
previously designed training activity, delivered using
the massive online open courses (MOOC) format,
Fig. 1 Flow diagram
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including basic concepts relating to multimorbidity,
appropriateness of prescribing, treatment adherence,
the Ariadne principles, and physician-patient shared
decision making.
– Second phase: Physician-patient interview based on
the Ariadne principles.
This intervention has been developed in accordance
with the recommendations and taxonomy proposed by
the Cochrane Effective Practice and Organisation of
Care Review Group (EPOC). The intervention is
described in detail in Fig. 2, following the approach pro-
posed by Perera et al. [36].
Control group
Patients in the control group will receive usual clinical
care based on the provision of advice and information
and will undergo examinations as recommended in the
CPGs corresponding to each of the patient’s chronic
diseases.
Variables
FPs will provide their data before the start of the study.
Patient data will be collected by the recruiting FP, who
will also be responsible for patient follow-up. All infor-
mation will be recorded in a case report form designed
for the study. Each FP will access the form from his/her
personal computer via the project website using a per-
sonal identification code. Three visits are defined for
patient data collection: baseline (T0), 6 months (T1),
and 12 months (T2) (see Table 1).
Primary outcome
Appropriateness of prescription will be measured by the
medication appropriateness index (MAI). The main out-
come variable will be evaluated by an independent FP
with training in the MAI. To ensure consistent ratings,
an analysis of intra-observer and inter-observer reliabil-
ity of evaluators will be conducted. Additionally, a FP
and a pharmacist will conduct a second appraisal of the
inter-observer reliability over a randomly selected 10%
of the completed questionnaires. This measure has been
proposed in other studies using the MAI [37].
Secondary outcomes
– Use of health services: unplanned and/or avoidable
hospitalizations, use of emergency services and PC
(FP and nurse).
– Quality of life: measured using the EuroQol 5D-5L
questionnaire [38, 39].
– Medication safety: measured as the incidence of
adverse drug reactions and potentially hazardous
interactions, classified using the taxonomy proposed
by Otero-López [40].
– Treatment adherence: measured using the Morisky-
Green test [41] and the Haynes-Sackett question-
naire [42].
– Patient perception of shared decision making:
measured using a single, multiple choice question,
formulated ad hoc.
– Cost-utility: time spent on training FPs, cost of
teaching staff, time spent on physician-patient inter-
views, utilities measured using the EuroQol 5D-5L.
Explanatory and adjustment variables
Patient (first level) variables
– Socio-demographics: age, sex, nationality, AC of
residence, marital status, socioeconomic status
(monthly salary expressed as multiples of the
minimum wage), family composition (number of
people living at home), housing indicators, social
support (Dukes-UNC-11 questionnaire adapted to
Spanish [43]), profession, and social class [44].
– Morbidity: number and description of chronic
diseases based on the International Classification
of Diseases in PC (ICPC).
– Pharmacotherapeutic treatment plan: number and
type of drugs prescribed, active ingredient, and dose
of each drug.
FP (second level) variables
– Socio-demographics: age, sex.
– Professional performance: years of professional
experience, tutor of residents (yes/no), average
workload measured as the average number of daily
consultations per FP during the year previous to the
start of the study.
– Prior training: in polypharmacy, multimorbidity,
and/or shared decision making.
Statistical analysis
All analyses will be carried out in accordance with
the intention-to-treat principle, with significance set
at p < 0.05.
Description of baseline characteristics (qualitative and
quantitative variables) of patients and professionals for
each arm of the study, with corresponding 95% confi-
dence interval (95% CI). Description of patients that
abandon the study, including patient characteristics and
reasons for loss during follow-up.
Basal comparison between groups using statistical tests
for independent samples (Student’s t test or chi-square
test). Tests for related samples (ANOVA for repeated
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measures) will be used to analyse changes within groups
and between visits.
Analysis of main effectiveness: between-group differ-
ence in T1-T0 MAI score, with corresponding 95% CI.
Multilevel analysis will be used to adjust models. Differ-
ence in MAI score will be considered the dependent
variable; baseline patient (first level) and FP (second
level) variables and treatment arm will be considered
fixed-effect independent variables; and grouping by FP
will be considered a random factor. Missing data
pertaining to professionals and/or patients will be ad-
dressed by replacing missing values with the most recent
available or baseline data.
Analysis of secondary effectiveness (non-confirma-
tory): between-group difference in means or proportions
of T2-T0 MAI score will be determined using the appro-
priate statistical tests and an explanatory model will be
adjusted using the same methodology applied to the
main outcome variable.
Estimated quality-adjusted life years (QALYs) gained at
the population level, with corresponding 95% CI, as
determined using parametric methods and bootstrap
techniques. Given the 1-year time horizon, no discount
rates will be applied.
Calculation of cost-utility ratio: this is an exploratory
objective for which a specific design has not been
applied. The cost-utility ratio will be estimated by divid-
ing the total cost by the sum of the potential gains
expressed in QALYs. A multivariate sensitivity analysis
will be performed in which costs will oscillate within the
Fig. 2 Complex intervention pat plot. QoL quality of life, MOOC Massive Online Open Courses
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range of uncertainty of a normal distribution. The
benefits (QALYs) will also oscillate within the same
range.
Discussion
This pragmatic clinical trial will involve the participation
of FPs from over 50 PC health centres in different
geographic areas of Spain, thus ensuring a high level of
external validity, given that the PC model implemented
throughout the country is relatively homogeneous.
To address the potential contamination among
patients of the same cluster, the FP is considered the
unit of randomization and the patient the unit of ana-
lysis. Still, there is evidence of contamination when
healthcare professionals working in the same teams are
randomized. To palliate this problem, the following
measures will be introduced. First, during the wel-
come and training session with all participating FPs,
we will avoid sharing too many details regarding the
complex intervention [45]. Second, participating FPs
will be asked to sign a confidentiality agreement once
they are randomly assigned to the intervention or
control group. Third, the intervention group will be
periodically reminded about the importance of avoiding
the exchange of any information with other participating
FPs during the intervention. Last, by signing the
researcher’s commitment, those FP eventually belonging
to the control group agree to receive the same training
activity once the intervention is over.
Due to the nature of the intervention, it cannot be
masked. However, outcome evaluation will be conducted
by skilled FPs and pharmacists that are blinded for treat-
ment allocation. The statistician conducting the analysis
will neither know to which study arm a given patient
has been assigned.
The variability in clinical practice of the different
physicians involved and their baseline knowledge on the
content covered in the intervention could result in lower
than expected differences between groups after comple-
tion of the intervention. To address this potential bias,
variables related to FPs’ prior training in polypharmacy,
multimorbidity, and/or shared decision making will be
collected and adjusted for in the multilevel model.
Furthermore, the MOOC format of the training material
will ensure homogenization of the training received by
the FPs. Video technology and online courses have
shown to be powerful tools to empower both patients
and health professionals and have the potential to sig-
nificantly improve the delivery of care in an increasingly
complex healthcare system [46].
FPs who agree to participate in an experimental
study are potentially more interested in the subject,
just as patients who agree to participate may share
certain common features in terms of health-related
awareness and motivation, which can lead to bias.
Although better results than those obtained including
less selective participants may occur, this phenomenon
would have a conservative effect (i.e. it would decrease
the magnitude of the difference between the two
groups). Moreover, participating FPs could modify or
improve their prescribing habits just as a response to
their awareness of being observed (Hawthorne effect).
This may dilute differences between intervention and
control groups regarding the appropriateness of
prescription.
Although the analysis of the effect of the intervention
on quality of life is non-confirmatory and the expected
changes are limited over a short period of time, we con-
sider it essential to include this outcome in the study.
Firstly, between-group differences may be detected
Table 1 Visit plan
T0 (baseline) T1 (6 months) T2 (12 months) Responsible entity
Confirm inclusion/exclusion criteria X FP
Written informed consent X FP
Socio-demographic variables X FP
Morbidity variables and drug treatment plan X X X FP
Randomization of FPs X RU
FP intervention (intervention group) X RT
Patient intervention (intervention group) X X FP
Use of health services X X X RT
Medication adherence X X X FP
Medication safety X X FP
Quality of life X X X FP
Costs X RT
MAI X X X EE
EC
FP family physician, RU research unit, RT research team, EE external evaluator, EC evaluation committee, MAI medication appropriateness index
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despite not being highly significant, and secondly, meas-
urement of quality of life changes allows the incorpor-
ation of outcome variables reported by patients
themselves, and facilitates the calculation of utilities for
the cost-utility analysis. This will enable responding to
some of the shortcomings and limitations of previous
interventions as detected by Patterson et al. [25].
It is essential to provide evidence concerning interven-
tions on PC patients with polypharmacy and multimor-
bidity, conducted in the context of routine clinical
practice, and involving young-old patients with signifi-
cant potential for preventing negative health outcomes.
Additional files
Additional file 1: Model of the informed consent completed by
participants. (DOC 51 kb)
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PCHC General Ricardos (Madrid): Francisco Ramón Abellán López, Carlos
Casado Álvaro, Paulino Cubero González, Santiago Manuel Machín
Hamalainen, Raquel Mateo Fernández, Mª Eloisa Rogero Blanco, Cesar Sánchez Arce.
PHHC Gregorio Marañón (Alcorcón): Elisa Ceresuela Wiesman.
PCHC Ibiza (Madrid): Jorge Olmedo Galindo.
PCHC Las Américas (Parla): Claudia López Marcos, Soledad Lorenzo Borda,
Juan Carlos Moreno Fernández, Belén Muñoz Gómez, Enrique Rodríguez
De Mingo.
PCHC Mª Ángeles López (Leganés): Juan Pedro Calvo Pascual, Margarita
Gómez Barroso, Beatriz López Serrano, Mª Paloma Morso Peláez, Fernando
Perales González, Julio Sánchez Salvador, Jeannet Dolores Sánchez Yépez,
Ana Sosa Alonso.
PCHC Mª Jesús Hereza (Leganés): Mª del Mar Álvarez Villalba.
PCHC Pavones (Madrid): Purificación Magán Tapia.
PCHC Pedro Laín Entralgo (Alcorcón): Mª Angelica Fajardo Alcántara, Mª
Canto De Hoyos Alonso, Rosario Iglesias González, Mª Aránzazu Murciano Antón.
PCHC Pintores (Parla): Manuel Antonio Alonso Pérez, Amaya Azcoaga
Lorenzo, Ricardo De Felipe Medina, Amaya Nuria López Laguna, Eva Martínez
Cid De Rivera, Iliana Serrano Flores, Mª Jesús Sousa Rodríguez.
PCHC Ramón y Cajal (Alcorcón): Mª Soledad Núñez Isabel, Jesús Mª Redondo
Sánchez, Pedro Sánchez Llanos, Lourdes Visedo Campillo.
Participating PCHCs and family physicians in Andalusia:
PCHC Alhaurín el Grande: Javier Martín Izquierdo, Macarena Toro Sainz.
PCHC Carranque: Mª José Fernández Jiménez, Esperanza Mora García, José
Manuel Navarro Jiménez.
PCHC Ciudad Jardín: Deborah Gil Gómez, Leovigildo Ginel Mendoza, Luz
Pilar de la Mota Ybancos, Jaime Sasporte Genafo.
PCHC Coín: Mª José Alcaide Rodríguez, Elena Barceló Garach, Beatriz
Caffarena de Arteaga, Mª Dolores Gallego Parrilla, Catalina Sánchez Morales.
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PCHC Delicias: Mª del Mar Loubet Chasco, Irene Martínez Ríos, Elena Mateo
Delgado.
PCHC La Roca: Esther Martín Aurioles.
PCHC Limonar: Sylvia Hazañas Ruiz.
PCHC Palmilla: Nieves Muñoz Escalante.
PCHC Puerta Blanca: Enrique Leonés Salido, Mª Antonia Máximo Torres, Mª
Luisa Moya Rodríguez, Encarnación Peláez Gálvez, José Manuel Ramírez
Torres, Cristóbal Trillo Fernández.
PCHC Tiro Pichón: Mª Dolores García Martínez Cañavate, Mª del Mar Gil
Mellado, Mª Victoria Muñoz Pradilla.
PCHC Vélez Sur: Mª José Clavijo Peña, José Leiva Fernández, Virginia Castillo
Romero.
PCHC Victoria: Rafael Ángel Maqueda, Gloria Aycart Valdés, Miguel
Domínguez Santaella, Ana Mª Fernández Vargas, Irene García García, Antonia
González Rodríguez, Mª Carmen Molina Mendaño, Juana Morales Naranjo,
Catalina Moreno Torres, Francisco Serrano Guerra.
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